However, the future success of PLK1 inhibitors as an HCC therapy will require additional information on the particular molecular vulnerability of patients and an understanding of the mechanisms of the disease in order to drive a rational approach for selecting the appropriate combinations of herbs. This evidence concerns the gene PLK1 and hepatocellular carcinoma.